The activity of this novel compound, named FA4, (Z)-2-(1-(4-(3 H-spiro[isobenzofuran-1,4’-piperidine]-1’-yl)butyl)-2-oxoindolin-3-ylidene)-N,N-dimethylhydrazinecarbothioamide (Fig. 1), was tested in a panel of pancreatic cancer cell lines and challenged with our most promising thiosemicarbazones, either targeting sigma-2 receptors (MLP44 and PS3) or not (ACthio-1). The gene discussed is TMEM97; the disease is familial pancreatic carcinoma.